Introduction
High-grade gliomas (HGGs), including the highly aggressive glioblastoma multiforme (GBM), represent the most common primary malignant brain tumors. They are characterized by a "three high and one low" profile: high incidence, high recurrence, high mortality, and a low cure rate. The standard of care—surgical resection followed by radiotherapy (RT) and temozolomide (TMZ) chemotherapy—often fails to prevent recurrence due to the invasive nature of HGG cells. Consequently, research has shifted toward "comprehensive treatment" strategies that combine precision radiotherapy with novel biological and physical interventions.
Evolution of Precision Radiotherapy
Radiotherapy remains a cornerstone of HGG management. Advances in imaging and computer technology have transitioned clinical practice from conventional 2D radiation to highly precise techniques:
- 3D Conformal RT (3D-CRT): Uses CT/MRI data to shape radiation beams to the tumor's volume.
- Intensity-Modulated RT (IMRT): The current standard, allowing for non-uniform beam intensities that "wrap" around irregular tumor shapes, maximizing the dose to the target while sparing adjacent critical structures like the brainstem or optic nerves.
- Stereotactic RT (SRT): Delivers high doses in fewer fractions, often used for small, localized recurrences.
Immunotherapy and Molecular Targeting
A paradigm shift in HGG treatment involves leveraging the immune system. Radiotherapy is now recognized as an "immune primer" that induces immunogenic cell death, releasing tumor antigens that can be targeted by the immune system.
Current strategies include:
- Immune Checkpoint Inhibitors: Drugs targeting PD-1/PD-L1 or CTLA-4 pathways to prevent the tumor from "switching off" the immune response.
- Vaccination Therapy: Using tumor stem cell lysates or specific antigens to train dendritic cells (DCs) and cytotoxic T lymphocytes (CTLs) to recognize and attack HGG cells.
- Molecular Targeted Therapy: Inhibitors targeting growth pathways such as VEGF (e.g., Bevacizumab) or EGFR, which are frequently dysregulated in gliomas.
Tumor-Treating Fields (TTFields)
TTFields represent a novel physical modality that uses low-intensity, intermediate-frequency (200 kHz) alternating electric fields. Unlike traditional therapies that target chemical pathways, TTFields exert mechanical forces on highly polar proteins like tubulin and septin.
During mitosis, these fields disrupt the formation of the mitotic spindle and the localization of the cleavage furrow. This leads to mitotic catastrophe, cytoplasmic blebbing, and ultimately, dielectrophoresis-induced cell death. The EF-14 Phase III trial demonstrated that adding TTFields to maintenance TMZ significantly improved both progression-free and overall survival in newly diagnosed GBM patients.
Clinical Outcomes and the Role of Biomarkers
The integration of these therapies has yielded measurable survival benefits:
- The Stupp Protocol: Established that adding TMZ to RT reduces the risk of death by 37%.
- MGMT Promoter Methylation: This genetic biomarker is a critical predictor of response; patients with methylated MGMT promoters derive significantly more benefit from TMZ.
- Recurrent HGG: For patients with recurrence, combinations like TTFields + TMZ have shown median overall survival (OS) of 20.9 months, a marked improvement over chemotherapy alone.
Challenges and Future Directions
Despite these advances, significant hurdles remain. The blood-brain barrier (BBB) continues to limit the delivery of many systemic agents. Furthermore, the molecular redundancy of HGGs allows them to bypass single-target therapies. Finally, the trade-off between aggressive treatment and neurocognitive preservation remains a central concern for clinicians.
Future research is focused on personalized "cocktail" therapies—combining patient-specific vaccines, TTFields, and ultra-precise IMRT—tailored to the unique molecular landscape of each tumor.
Summary updated